Literature DB >> 9542937

Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.

R S Tedder1, S Kaye, C Loveday, I V Weller, D Jeffries, J Norman, J Weber, M Bourelly, R Foxall, A Babiker, J H Darbyshire.   

Abstract

Virological assays for human immunodeficiency virus type 1 load and drug resistance can broadly be divided into culture-based and molecular biology-based methods. Culture-based methods give a direct measure of infectious virus load and phenotypic drug resistance, whereas molecular biology-based methods are indirect, assaying nucleic acid levels to determine virus load and point mutations associated with drug resistance. We have compared culture-based and non-culture-based methods for patients enrolled in a placebo-controlled trial of zidovudine (the Concorde Trial). Virus loads were assayed by culture of peripheral blood mononuclear cells (PBMCs) or quantitative PCR, and drug resistance was assayed in culture or in a quantitative, PCR-based point mutation assay. The rates of detection of viremia and drug resistance were higher by PCR than by culture for this population of subjects. Comparison of the virus loads by the two measures showed a good correlation for virus loads in PBMCs but a poor correlation for virus loads in plasma. The latter result probably reflected the inaccuracies of culture in assaying plasma with the low infectious virus titers seen in the study population. The concordance of phenotypic and genotypic drug resistance methods was high, with all phenotypically resistant isolates having at least one resistance-associated mutation and with no mutations being found in a drug-sensitive isolate. Genomic resistance scores (weighted sums of levels of resistance mutations) showed good correlations with the levels of phenotypic resistance, and both resistance measures were observed to increase as the duration of exposure to drug increased. Overall, non-culture-based methods were shown to correlate well with culture-based methods and offer a low-cost, high-throughput alternative. However, culture-based methods remain the final arbiters of infectious virus load and phenotypic drug resistance and are unlikely to be superseded entirely.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9542937      PMCID: PMC104689          DOI: 10.1128/JCM.36.4.1056-1063.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.

Authors:  B A Larder; A Kohli; P Kellam; S D Kemp; M Kronick; R D Henfrey
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

2.  HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials.

Authors:  M G Semple; S Kaye; C Loveday; R S Tedder
Journal:  J Virol Methods       Date:  1993-02       Impact factor: 2.014

3.  Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals.

Authors:  P D Bieniasz; K Ariyoshi; M A Bourelly; S Bloor; R B Foxall; E C Harwood; J N Weber
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

4.  Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.

Authors:  S Aoki-Sei; R Yarchoan; S Kageyama; D T Hoekzema; J M Pluda; K M Wyvill; S Broder; H Mitsuya
Journal:  AIDS Res Hum Retroviruses       Date:  1992-07       Impact factor: 2.205

5.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.

Authors:  V W Byrnes; V V Sardana; W A Schleif; J H Condra; J A Waterbury; J A Wolfgang; W J Long; C L Schneider; A J Schlabach; B S Wolanski
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.

Authors:  M Holodniy; D Katzenstein; M Winters; J Montoya; R Shafer; M Kozal; M Ragni; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-04

8.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment.

Authors:  D A Katzenstein; M Holodniy; D M Israelski; S Sengupta; L A Mole; J L Bubp; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

10.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Authors:  P Kellam; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more
  2 in total

1.  Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial.

Authors: 
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

2.  Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).

Authors:  Ume L Abbas; Gregory Hood; Arthur W Wetzel; John W Mellors
Journal:  PLoS One       Date:  2011-04-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.